GlobeNewswire by notified

Rizobacter contributes its biological technologies to the take-off of African agriculture

Share

The company leads the inoculants market in South Africa and commercializes its products in eight other countries. It has consolidated its presence in the region through alliances with key players to reach growers and to open new markets.

LAKE FOREST, Ill., April 21, 2022 (GLOBE NEWSWIRE) -- The African continent is home to 60% of the arable land on the entire planet; its productive potential is as great as the knowledge, infrastructure, and technology gaps experienced by its farmers. Rizobacter landed in this territory full of contrasts and opportunities, deploying a commercial strategy, plus an almost militant attitude, with the objective of introducing its sustainable technologies. The leading Argentine agricultural microbiology company arrived in South Africa with inoculants for soybeans over 12 years ago. It achieved a high degree of adherence to the practice and today it occupies 65% of the market share. "Unlike in other countries on the continent, in South Africa, growers have infrastructure, machinery, and access to good input technologies and knowledge; they value quality greatly. In the last two years, we have managed to occupy from 50 to 65% of the inoculant market. Our technologies and quality are highly recognized; there, we are leaders in seeds treatment with biologicals," says Ignacio Ardanaz, Africa Business Development Manager, in charge of a busy agenda that brings together trade agreements and multiple trials of new nutrition and protection technologies for a variety of crops such as soybean, corn, potato, bean, tomato, and peanut, among others.

In the last two years, it has also gained a foothold in eight other African countries: Malawi, Zambia, Nigeria, Ghana, Uganda, Kenya, Sierra Leone, and Tanzania. In these markets, however, the company found a different reality. Commercial farms are scarce, whereas small-scale farms, of just over one hectare, are predominant. Growers practice subsistence agriculture and lack specific training, quality seeds, and access to technology.

In order to reach them, the company cooperates with local actors, such as distribution companies, and with public and non-governmental organizations that conduct technology transfer programs and support plans for small growers willing to update their family-run farms and improve their performance.

Our presence in these countries responds to a company strategy of reaching all farmers; not just those from the most developed markets. Our purpose is that small growers also benefit from the impact of our technologies,” Ardanaz remarks.

By incorporating inoculants into the seeds, Rizobacter offers them productivity gains and logistical benefits that have repercussions on both their economy and their sustainability practices for soil and crop care. Habitually, African smallholder producers resort to using urea for fertilization. This product has a high environmental impact because its production process, based on fossil fuels, emits polluting gases; it also causes a high economic cost that affects profitability. Transporting the heavy bags of nitrogen fertilizer to their plots is not an easy task either, since their usual means of transport are bicycles and motorbikes.

Seed inoculation appears as a sustainable practice that covers the nitrogen needs for crop development through the natural process of biological fixation, with no negative impact on the environment. In addition, it helps farmers stabilize their yields in a way that is consistent with their economic possibilities (because of the benefit/cost ratio) and infrastructure, since the bladders can be easily transported in the vehicles at their disposal.

Even though inoculants are the flagship products, biostimulants that favor phosphorus release in crops such as fruit trees, potato, wheat, and barley, are showing an excellent performance that is verified in higher yields and quality production.

Alliances, the key to growth

Ardanaz points out that "The demand for new technologies exists; what must be done is find the local partner to penetrate the market." Therefore, it is key to join forces with local actors and build a critical mass to institute a change in the traditional agriculture structure that dominates in the region.

Local companies have their own distribution force, known as “foot soldiers.” They are in charge of touring the villages and contacting the farmers. But their job is not limited to sales; they are also involved in training, a task in which Rizobacter also participates by organizing local demonstrations and talks on the impact of biotechnologies.

Among the cooperation alliances maintained by the company, is the relationship with Warc, an organization dedicated to training with the mission of lifting African subsistence farmers out of poverty. It is also linked to the International Institute of Tropical Agriculture (IITA), which aims to solve hunger and poverty.

In Africa, Rizobacter also has strong links with leading multinational companies such as Syngenta, with which it is expanding the commercial alliance to different regions of the continent. Together, they conduct joint testing of technologies that are associated with the treatment of seeds. It is also a strategic sponsor of the Soybean Innovation Lab initiative, a non-profit organization that brings together actors in the soybean value chain with the purpose of developing this crop in African soil. Through this participation, the company has reached more than 24 countries.

In Africa, agriculture is booming. It takes time, patience, and investment to reach farmers, and Rizobacter is willing to do so," said Ardanaz. His agenda has no rest. For this year, the company plans to reach nine more countries with various products, so as to become a strong player in the take-off of agriculture in a region that needs to expand its production frontier and improve its yields, by implementing a sustainable production system.

Lionel Thomas Robinson
International Marketing Manager at Rizobacter
lthomas@rizobacter.com
www.rizobacter.us

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vapers deliver an open letter to Swedish Members of the Parliament and ask to stop the vaping flavour ban25.5.2022 09:10:17 CEST | Press release

Stockholm, Sweden, May 25, 2022 (GLOBE NEWSWIRE) -- Yesterday, the global vaping advocacy group World Vapers Alliance delivered an open letter to the Swedish parliament urging policymakers to stop the flavour ban. World Vapers’ Alliance held another protest today to stand against the ban on vape flavours. The group marched in front of the Parliament with the slogan “Flavours help smokers quit” during parliament's session and delivered an open letter to members of parliament to urge them to vote against the ban. Earlier this year, the Swedish government introduced a bill that would prohibit all non-tobacco vape flavours in nicotine and non-nicotine products. If approved, the bill is set to enter into force on 1 January 2023. “I benefited first hand from vaping and managed to stay smoke free for the last few years. Like most other smokers, I tried to find a way out of cigarettes - but nothing worked for me, the patches, the gums, the inhalers. Vaping - and especially combined with flavou

Kalera - Last day of trading in Kalera AS' shares on Euronext Growth Oslo25.5.2022 08:00:00 CEST | Press release

OSLO, Norway, May 25, 2022 (GLOBE NEWSWIRE) -- Reference is made to the stock exchange announcement published by Kalera AS (the "Company") (Euronext Growth Oslo: KAL, Bloomberg: KSLLF) on 13 May 2022 regarding the merger with its wholly-owned Luxembourg subsidiary Kalera S.A. (the "Merger"). The Merger will become effective upon publication of the minutes from Kalera S.A.'s general meeting approving the Merger in accordance with Luxembourg law. Such publication, and the effectiveness of the Merger, is expected to occur on 27 May 2022 (the "Effectiveness"). The last day of trading in the Company's shares on Euronext Growth Oslo is today, 25 May 2022. A trading suspension will be imposed by the Oslo Stock Exchange following end of trading today, and the trading suspension will remain in force until the Effectiveness. As of the Effectiveness, all of the Company's assets, rights and liabilities will be transferred to Kalera S.A., and the Company will be dissolved and have it shares deliste

Reminder of an Investor Conference Webinar25.5.2022 08:00:00 CEST | Press release

We would like to remind that KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. How to join the webinar? To join the webinar, please register via following link: https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to register on the Zoom platform. The webinar will be recorded and available online for everyone at the company’s website on www.kn.lt and on Nasdaq Baltic youtube.com account. What is a corporate webinar? A corporate webinar is a virtual conference, du

Saniona publishes its interim report for the first quarter of 202225.5.2022 08:00:00 CEST | Press release

Q12022 (Q12021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M)Loss per share was SEK -2.14 (-1.34)Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD) stage and the Positron Emission Tomography (PET) stage of its Phase 1 trial of SAN711; The ongoing Phase 1 trial is placebo-controlled, and the data remain blinded. Saniona continues to expect data from the trial by mid-2022.Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartis’s January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake. This payment, in addition to the previously received SEK 24.2 million (US$2.9 million), together complete Saniona’s portion of the upfront payment connected to the acquisition. Saniona may also receive a portion of the remaining SEK 5.1 billion (US$560 million) in contingent payments associated with the achie

Saniona publicerar sin delårsrapport för det första kvartalet 202225.5.2022 08:00:00 CEST | Pressemelding

Q1 2022 (Q1 2021) Intäkter uppgick till 6,6 MSEK (3,4 M)Rörelseresultat uppgick till -133,2 MSEK (-94,1 M) Periodens resultat uppgick till -133,4 MSEK (-83,4 M)Resultat per aktie uppgick till -2,14 SEK (-1,34)Resultat per aktie efter utspädning uppgick till -2,14 SEK (-1,34) Väsentliga händelser under Q1 2022 Saniona inledde upprepad dosering med doseskalering (MAD) samt undersökningar med positronemissionstomografi (PET) i Fas 1-studien med SAN711; den pågående Fas 1-studien är placebokontrollerad och data är fortfarande blindade. Saniona räknar fortsatt med att få tillgång till data från studien under mitten av 2022.Saniona erhöll 7,3 MSEK (0,8 MUSD) från Novartis relaterat till Novartis förvärv av Cadent Therapeutics i januari 2021, där Saniona hade en ägarandel på 3 procent. Denna betalning, utöver de tidigare erhållna 24,2 MSEK (2,9 MUSD), utgör tillsammans Sanionas del av förskottsbetalningen kopplad till förvärvet. Saniona kan också komma att erhålla en andel av de återstående 5